BLRX (BioLineRx Ltd.) stock: $2.49, $12.1M market cap, $3.2M cash, $14.7M EV, $17.4M fully diluted market cap. Data from Fully Diluted's biotech stocks database.
Pipeline assets
Motixafortide
Approved · Active Modality: peptide
Aliases APHEXDA
Target CXCR4
Partnerships Biokine Therapeutics: in-license; Ayrmid License Agreement (November 2024): global rights ex-Asia, all indications other than solid tumors; Gloria License Agreement (October 2023): substantially all of Asia, all indications (planned motixafortide PDAC study in China not advancing on schedule)
Indications- Stem-cell mobilization for autologous transplantation in multiple myeloma (Approved)
- Solid tumors (Stage not disclosed)
Status note FDA approved September 8, 2023 (with filgrastim). US commercialization shut down after November 2024 Ayrmid out-license; operations refocused on Israel development. AML indication discontinued; company still sees CXCR4 as viable in other AML lines.
GLIX1
Stage not disclosed · Active Modality: small molecule (oral)
Target DNA damage response
Partnerships Hemispherian AS: September 2025 collaboration for development, clinical evaluation and commercialization; BioLineRx required to invest $5M in Tetragon Biosciences (GLIX1 vehicle) within 36 months or face equity reduction/repurchase
Indications- Glioblastoma (GBM) (Stage not disclosed)
- Other solid tumors (Stage not disclosed)
Status note First-in-class oral small molecule targeting DNA damage response; no clinical trial disclosed in this filing.
BL-5010
Stage not disclosed · Active
Partnerships Innovative Pharmaceutical Concepts, Inc.: in-license
Indications- not disclosed (Stage not disclosed)
Status note In-licensed candidate; no development status disclosed in this filing.
Per-asset detail extracted from the 20-F filed 2026-03-23. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.